Affiliation:
1. Department of Health Surveillance and Bioethics, Forensic Toxicology Laboratory Università Cattolica del Sacro Cuore F. Policlinico Gemelli IRCCS Rome Italy
2. Department of Translational Medicine, Section of Legal Medicine, LTTA Center and University Center of Gender Medicine University of Ferrara Ferrara Italy
3. Collaborative Center for the Italian National Early Warning System, Department of Anti‐Drug Policies Presidency of the Council of Ministers Milan Italy
Abstract
AbstractThe metabolism of 3‐chloromethcathinone (3‐CMC) was studied after controlled administration in a murine model using the dried blood spot (DBS) technique for the sampling, storage and purification of blood samples. Liquid chromatography–high‐resolution mass spectrometry (LC‐HRMS) was used for the identification of metabolites and investigation of their fragmentation pattern. Subsequently, a liquid chromatography–tandem mass spectrometry (LC‐MS/MS) method was developed for their identification and 3‐CMC quantification in routine workload. The main metabolites identified were two stereoisomers of dihydro‐CMC, N‐demethyl‐CMC, and dihydro‐N‐demethyl‐CMC. The stability of 3‐CMC and of its metabolites deposited on DBS was evaluated by replicate analyses after 30, 50, and 90 days, demonstrating a decrease in concentration. It was more pronounced for 3‐CMC, with −67% and −82% percentage deviation from the initial concentrations, and for N‐demethyl 3‐CMC (decrease comprised between −48% and −88%) than for the di‐hydro metabolites, ranging from −5% to −37%. Regardless, all of them were detectable till 90 days after deposition as DBS. The possibility of identifying 3‐CMC and its metabolites with high sensitivity is an invaluable tool for the diagnosis of exposure to the substance, also in low doses or after some hours, and for various applications in clinical and forensic toxicology, such as driving under the influence, drug‐facilitated crimes, and addiction to intoxications. DBS demonstrated to be a reliable technique for the sampling, storage, and purification of the blood specimen for 3‐CMC and metabolite detection.
Reference20 articles.
1. EMCDDA.European drug report 2023 – new psychoactive substances.2023.https://www.emcdda.europa.eu/publications/european-drug-report/2023/new-psychoactive-substances_en
2. EMCDDA.European drug report 2023 – synthetic stimulants.2023.https://www.emcdda.europa.eu/publications/european-drug-report/2023/synthetic-stimulants_en#level-2-section2
3. UNODC.Special points 2023 world drug report: key messages 2023 world drug report: 15.2023.
4. 3-Methylmethcathinone—Interpretation of Blood Concentrations Based on Analysis of 95 Cases
5. EMCDDA.Report on the risk assessment of 1‐(3‐chlorophenyl)‐2‐(methylamino)propan‐1‐one (3‐chloromethcathinone 3‐CMC) in accordance with article 5c of regulation (EC) no 1920/2006 (as amended).2022.10.2810/671114